JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Income Statement
Earnings Waterfall
JW (Cayman) Therapeutics Co Ltd
Revenue
|
173.9m
CNY
|
Cost of Revenue
|
-85.6m
CNY
|
Gross Profit
|
88.2m
CNY
|
Operating Expenses
|
-695.7m
CNY
|
Operating Income
|
-607.5m
CNY
|
Other Expenses
|
-160.5m
CNY
|
Net Income
|
-768m
CNY
|
Income Statement
JW (Cayman) Therapeutics Co Ltd
Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue |
0
N/A
|
0
N/A
|
31
N/A
|
97
+214%
|
146
+51%
|
167
+15%
|
174
+4%
|
|
Gross Profit | ||||||||
Cost of Revenue |
0
|
0
|
(22)
|
(65)
|
(87)
|
(87)
|
(86)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
9
N/A
|
32
+256%
|
59
+83%
|
80
+37%
|
88
+10%
|
|
Operating Income | ||||||||
Operating Expenses |
(476)
|
(651)
|
(783)
|
(809)
|
(756)
|
(745)
|
(696)
|
|
Selling, General & Administrative |
(242)
|
(311)
|
(368)
|
(391)
|
(362)
|
(312)
|
(178)
|
|
Research & Development |
(214)
|
(314)
|
(391)
|
(390)
|
(367)
|
(394)
|
(414)
|
|
Depreciation & Amortization |
(14)
|
(18)
|
(27)
|
(40)
|
(49)
|
(54)
|
(75)
|
|
Other Operating Expenses |
(6)
|
(8)
|
4
|
12
|
23
|
16
|
(29)
|
|
Operating Income |
(476)
N/A
|
(651)
-37%
|
(774)
-19%
|
(777)
0%
|
(697)
+10%
|
(665)
+5%
|
(607)
+9%
|
|
Pre-Tax Income | ||||||||
Interest Income Expense |
(3)
|
63
|
72
|
(74)
|
(149)
|
(133)
|
22
|
|
Non-Reccuring Items |
6
|
0
|
0
|
0
|
(0)
|
0
|
(182)
|
|
Total Other Income |
(1 191)
|
(706)
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(1 664)
N/A
|
(1 294)
+22%
|
(702)
+46%
|
(851)
-21%
|
(846)
+1%
|
(797)
+6%
|
(768)
+4%
|
|
Net Income | ||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(1 664)
|
(1 294)
|
(702)
|
(851)
|
(846)
|
(797)
|
(768)
|
|
Net Income (Common) |
(1 664)
N/A
|
(1 294)
+22%
|
(702)
+46%
|
(851)
-21%
|
(846)
+1%
|
(797)
+6%
|
(768)
+4%
|
|
EPS (Diluted) |
-12.61
N/A
|
-3.27
+74%
|
-1.76
+46%
|
-2.09
-19%
|
-2.06
+1%
|
-1.94
+6%
|
-1.87
+4%
|